RoosterBio and Thermo Fisher: A Game-Changing Collaboration
RoosterBio, Inc., a prominent supplier of adult human mesenchymal stem/stromal cells (hMSCs), has announced a strategic collaboration with Thermo Fisher Scientific. This partnership aims to enhance the manufacturing processes for groundbreaking cell and exosome therapies, promising to make significant advances in the treatment of degenerative diseases.
Enhancing Therapy Development
This collaboration combines RoosterBio’s robust portfolio of hMSC products and advanced processes with Thermo Fisher’s expertise in GMP contract manufacturing. This partnership underscores a shared goal to streamline the development and manufacturing of critical therapeutic solutions.
With this alliance, biopharmaceutical companies will benefit from RoosterBio's specialization in hMSCs and exosome technologies, coupled with Thermo Fisher’s efficient GMP manufacturing services. These services encompass the entire spectrum, from upstream expansion of hMSCs to the downstream purification of MSC-derived exosomes, eventually leading to the production of drug products.
Driving Innovation in Biotechnology
Tim Kelly, CEO of RoosterBio, expressed enthusiasm about this collaboration by noting, "Thermo Fisher has a stellar record in manufacturing clinical and commercial cell and gene therapies and possesses a global infrastructure to support our clients' needs. Our partnership is poised to deliver comprehensive, flexible bioprocessing solutions tailored for biopharmaceutical companies striving to advance engineered cell and exosome therapies." This sentiment reflects the shared ambition between both companies to pave the way for advanced therapy products accessible to patients globally.
Commitment to Patient-Centric Outcomes
Ben Castro, Vice President at Thermo Fisher, remarked on the collaboration’s significance, saying, "This partnership highlights our dedication to ensuring that transformative therapies reach patients efficiently and safely. We are enthusiastic about expanding our Contract Development Manufacturing Organization (CDMO) services to bolster our biotechnology partners throughout the lifespan of research, development, and manufacturing of critical treatments."
Prioritizing Safety and Efficacy
At RoosterBio, the focus on safety and effectiveness is paramount. The company adheres to global best practices, ensuring that hMSCs are sourced under strict regulatory guidelines. Additionally, the manufacturing processes employed are highly standardized and backed by comprehensive characterization protocols, echoing their commitment to bioethics.
About RoosterBio
RoosterBio accelerates the development of human mesenchymal stem/stromal cells (hMSCs) and extracellular vesicle (EV) products, facilitating the rapid transition to scalable advanced therapies. The company’s high-quality hMSCs, customized bioprocess media, and genetic engineering tools are complemented by in-depth bioprocessing expertise, guiding therapeutic developers from concept to first-in-human tests and eventually to commercial manufacturing with enhanced productivity and lowered costs. Equipped with optimized, scalable processes, Type II Master Files, and cGMP products, RoosterBio empowers therapeutic programs to move towards clinical trials in a year or less. The overarching vision behind RoosterBio is to create a future where safe and effective regenerative medicines are quickly developed and made available to patients worldwide.
Frequently Asked Questions
What is the aim of the collaboration between RoosterBio and Thermo Fisher?
The collaboration focuses on enhancing the manufacturing of cell and exosome therapies, aiming to accelerate the availability of innovative treatment options for degenerative diseases.
What are key services provided through this partnership?
The partnership includes upstream expansion of hMSCs, downstream purification processes, and overall drug product manufacturing, leveraging the strengths of both companies.
How does RoosterBio ensure the quality of its products?
RoosterBio prioritizes product safety by sourcing hMSCs under strict guidelines and utilizing standardized manufacturing processes, along with first-class product characterization.
Who leads RoosterBio?
Tim Kelly serves as the Chief Executive Officer of RoosterBio, guiding the company’s vision and strategic collaborations.
What is RoosterBio's mission?
RoosterBio's mission is to accelerate the development of hMSC and EV therapies, making high-quality regenerative medicines widely available and accessible to patients around the world.
